interferon alfa 2a

Summary

Summary: A recombinant alfa interferon consisting of 165 amino acids with lysine at position 23 and histidine at position 34. It is used extensively as an antiviral and antineoplastic agent.

Top Publications

  1. ncbi Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
    M P Manns
    Division of Gastroenterology and Hepatology, Medical School of Hannover, Hannover, Germany
    Lancet 358:958-65. 2001
  2. ncbi Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
    Michael W Fried
    University of North Carolina, Chapel Hill 27599, USA
    N Engl J Med 347:975-82. 2002
  3. ncbi Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
    George K K Lau
    Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong SAR, China
    N Engl J Med 352:2682-95. 2005
  4. ncbi Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    Ann Intern Med 140:346-55. 2004
  5. ncbi Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
    Bernard Escudier
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Lancet 370:2103-11. 2007
  6. ncbi Structural and biologic characterization of pegylated recombinant IFN-alpha2b
    M Grace
    Biotechnology Development, Schering Plough Research Institute, Union, NJ 07083, USA
    J Interferon Cytokine Res 21:1103-15. 2001
  7. ncbi Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin
    Jian Wu Yu
    Department of Infectious Diseases, Second Affiliated Hospital, Harbin Medical University, Nangang District, Harbin, China
    J Gastroenterol Hepatol 22:832-6. 2007
  8. ncbi Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients
    Francesca J Torriani
    Department of Medicine, Division of Infectious Diseases, University of California, San Diego, Antiviral Research Center, CA 92103, USA
    N Engl J Med 351:438-50. 2004
  9. ncbi Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels
    Stefan Zeuzem
    Saarland University Hospital, Homburg Saar, Germany
    Gastroenterology 127:1724-32. 2004
  10. ncbi Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B
    W G E Cooksley
    Royal Brisbane Hospital, Herston, Queensland, Australia
    J Viral Hepat 10:298-305. 2003

Research Grants

Detail Information

Publications237 found, 100 shown here

  1. ncbi Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
    M P Manns
    Division of Gastroenterology and Hepatology, Medical School of Hannover, Hannover, Germany
    Lancet 358:958-65. 2001
    ..In this randomised trial, peginterferon alfa-2b plus ribavirin was compared with interferon alfa-2b plus ribavirin...
  2. ncbi Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
    Michael W Fried
    University of North Carolina, Chapel Hill 27599, USA
    N Engl J Med 347:975-82. 2002
    ..We compared the efficacy and safety of peginterferon alfa-2a plus ribavirin, interferon alfa-2b plus ribavirin, and peginterferon alfa-2a alone in the initial treatment of chronic hepatitis C...
  3. ncbi Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
    George K K Lau
    Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong SAR, China
    N Engl J Med 352:2682-95. 2005
    ....
  4. ncbi Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    Ann Intern Med 140:346-55. 2004
    ..Treatment with pegylated interferon (peginterferon) and ribavirin for 48 weeks is more effective than conventional interferon and ribavirin in patients with chronic hepatitis C...
  5. ncbi Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
    Bernard Escudier
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Lancet 370:2103-11. 2007
    ..Therefore, an investigation of the combination treatment of the humanised anti-VEGF monoclonal antibody bevacizumab with interferon alfa was warranted...
  6. ncbi Structural and biologic characterization of pegylated recombinant IFN-alpha2b
    M Grace
    Biotechnology Development, Schering Plough Research Institute, Union, NJ 07083, USA
    J Interferon Cytokine Res 21:1103-15. 2001
    ..These results demonstrate that PEG Intron maintains an in vitro biologic potency profile for both antiviral and immunotherapeutic activity that is highly comparable to that of Intron A...
  7. ncbi Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin
    Jian Wu Yu
    Department of Infectious Diseases, Second Affiliated Hospital, Harbin Medical University, Nangang District, Harbin, China
    J Gastroenterol Hepatol 22:832-6. 2007
    ..The aim of this study was to investigate the predictive value of rapid virological response (RVR) and early virological response (EVR) on sustained virological response (SVR) in HCV patients treated with peg-IFN-alpha-2a and ribavirin...
  8. ncbi Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients
    Francesca J Torriani
    Department of Medicine, Division of Infectious Diseases, University of California, San Diego, Antiviral Research Center, CA 92103, USA
    N Engl J Med 351:438-50. 2004
    ....
  9. ncbi Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels
    Stefan Zeuzem
    Saarland University Hospital, Homburg Saar, Germany
    Gastroenterology 127:1724-32. 2004
    ....
  10. ncbi Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B
    W G E Cooksley
    Royal Brisbane Hospital, Herston, Queensland, Australia
    J Viral Hepat 10:298-305. 2003
    ..These results indicate that peginterferon alpha-2a (40 kDa) is superior in efficacy to conventional interferon alpha-2a in chronic hepatitis B based on clearance of HBeAg, suppression of HBV DNA, and normalization of ALT...
  11. ncbi Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients
    Montserrat Laguno
    Infectious Diseases Service, Hospital Clinic, Barcelona, Spain
    Hepatology 49:22-31. 2009
    ..Side effects were present in 96% of patients but led to treatment discontinuation in 10% of patients (8% on PEG 2b and 13% on PEG 2a, P = 0.47)...
  12. ncbi Side effects of therapy of hepatitis C and their management
    Michael W Fried
    Division of Digestive Diseases, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Hepatology 36:S237-44. 2002
    ..Strategies to maximize adherence are being developed and, in the future, may include early identification of and therapy for depression and the selective use of hematopoietic growth factors to ameliorate hematologic abnormalities...
  13. ncbi Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)
    J Atzpodien
    Medizinische Hochschule Hannover, Germany
    J Clin Oncol 22:1188-94. 2004
    ..We conducted a prospectively randomized clinical trial to compare the efficacy of three outpatient therapy regimens in 341 patients with progressive metastatic renal cell carcinoma...
  14. ncbi Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
    Gastroenterology 132:103-12. 2007
    ..However, prior studies did not assess the impact of reducing the dose of peginterferon independent of ribavirin or differentiate between dose reduction or interrupting or prematurely discontinuing treatment...
  15. ncbi Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C
    John G McHutchison
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
    Gastroenterology 123:1061-9. 2002
    ..We evaluated the impact of adherence to combination therapy with interferon or peginterferon plus ribavirin in chronic hepatitis C patients...
  16. ncbi [Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea]
    Hyuk Lee
    Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    Korean J Hepatol 12:31-40. 2006
    ..We evaluated the efficacy and safety of administering peginterferon alfa-2a plus ribavirin in native Korean patients with chronic hepatitis C...
  17. ncbi Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1
    Hari S Conjeevaram
    Division of Gastroenterology, The University of Michigan, Ann Arbor, Michigan 48109 0362, USA
    Gastroenterology 131:470-7. 2006
    ..Compared with Caucasian Americans (CA), African Americans (AA) with chronic hepatitis C are less likely to respond to interferon-based antiviral therapy...
  18. ncbi IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection
    Martin Lagging
    Department of Infectious Diseases, University of Goteborg, Sweden
    Hepatology 44:1617-25. 2006
    ..Thus, pretreatment IP-10 analysis may prove helpful in decision-making regarding pharmaceutical intervention...
  19. ncbi Peginterferon alfa-2a in patients with chronic hepatitis C
    S Zeuzem
    Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt, Germany
    N Engl J Med 343:1666-72. 2000
    ..We compared the clinical effects of a regimen of peginterferon alfa-2a with those of a regimen of interferon alfa-2a in the initial treatment of patients with chronic hepatitis C...
  20. ncbi Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C
    K Rajender Reddy
    Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Adv Drug Deliv Rev 54:571-86. 2002
    ..Peginterferon alfa-2a (40 KD) has comparable safety to interferon alfa-2a. The addition of ribavirin to peginterferon alfa-2a (40 KD) further enhances the therapeutic benefit for patients with hepatitis C...
  21. ncbi Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C
    A M Di Bisceglie
    Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, St Louis, MO 63110, USA
    J Viral Hepat 14:721-9. 2007
    ....
  22. ncbi Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection
    Ana I Romero
    Department of Virology, University of Goteborg, Goteborg, Sweden
    J Infect Dis 194:895-903. 2006
    ..We investigated associations between interferon (IFN)-gamma-inducible protein (IP)-10 and liver histological results, viral kinetic response, and treatment outcome in patients infected with hepatitis C virus (HCV) genotypes 1-4...
  23. ncbi Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C
    Maribel Rodriguez-Torres
    Fundacion de Investigacion de Diego, San Juan, Puerto Rico
    N Engl J Med 360:257-67. 2009
    ..We evaluated the effect of Latino ethnic background on the response to treatment with peginterferon alfa-2a and ribavirin in patients infected with HCV genotype 1 who had not been treated previously...
  24. ncbi Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy
    Donald M Jensen
    Center for Liver Diseasees, University of Chicago Hospitals, 60637, USA
    Hepatology 43:954-60. 2006
    ..In conclusion, patients infected with HCV genotype 1 and treated with peginterferon alpha-2a/ribavirin sustained a RVR 24% of the time. This portends an 89% probability of a SVR after 24 weeks of treatment...
  25. ncbi Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, Paris, France
    Hepatology 38:75-85. 2003
    ..In conclusion, sustained disappearance of the virus is associated with reduction of steatosis in genotype 3 as well as a correction of baseline low serum cholesterol...
  26. ncbi Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3
    Mitchell L Shiffman
    Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
    N Engl J Med 357:124-34. 2007
    ..We conducted a large, randomized, multinational, noninferiority trial to determine whether similar efficacy could be achieved with only 16 weeks of treatment with peginterferon alfa-2a and ribavirin...
  27. pmc Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy
    J M Pawlotsky
    Department of Bacteriology and Virology, Hopital Henri Mondor, Universite Paris XII, 94010 Creteil, France
    J Virol 73:6490-9. 1999
    ..These changes are associated with profound alterations of the natural outcome of HCV-related liver disease, raising the hypothesis of a causal relationship...
  28. ncbi Pegylated interferons: what role will they play in the treatment of chronic hepatitis C?
    M L Shiffman
    Hepatology Section, Medical College of Virginia Commonwealth University, Box 980341, Richmond, VA 23298, USA
    Curr Gastroenterol Rep 3:30-7. 2001
    ..The role PEG-interferons will play in patients who have either relapsed or failed to respond to previous interferon or interferon/ribavirin therapy remains to be defined...
  29. ncbi Low-dose cyclophosphamide and interferon alfa 2a for the treatment of capillary hemangioma of the orbit
    Matthew W Wilson
    Department of Ophthalmology, University of Tennessee Health Science Center, Memphis, Tennessee 38163, USA
    Ophthalmology 114:1007-11. 2007
    To report the use of a combination of low-dose cyclophosphamide and interferon alfa 2a (IFNalpha2a) for the treatment of orbital juvenile capillary hemangioma.
  30. ncbi An unusual side effect of interferon alfa 2A: digital clubbing
    Mohammad Tanveer Alam
    Medical Unit V, Civil Hospital, Karachi, Pakistan
    J Ayub Med Coll Abbottabad 20:165-6. 2008
    ..No national or international data regarding such unusual side effect is available. Whether this effect is idiosyncratic or dose related and whether it is reversible or not after completion of treatment is yet to be established...
  31. ncbi Efficacy and tolerance of HCV treatment in HIV-HCV coinfected patients: the potential interaction of PI treatment
    I Poizot-Martin
    CISIH Sud, Département de Recherche Clinique RCCS, Hopital Sainte Marguerite, CHU de Marseille, France
    HIV Clin Trials 4:262-8. 2003
    ..To evaluate tolerance and efficacy of an open-label interferon-ribavirin treatment and their determinants in 62 HCV-HIV coinfected patients in routine followup...
  32. ncbi Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD)
    K Rajender Reddy
    Gastrointestinal Division, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Semin Liver Dis 24:33-8. 2004
    ..The much-increased sustained virological response rates observed with pegylated IFN alfa-2a (40 kD) and pegylated IFN alfa-2b (12 kD) support the rationale for pegylation of IFN...
  33. ncbi Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma
    Bernard Escudier
    Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805, Villejuif, France
    J Clin Oncol 27:1280-9. 2009
    ....
  34. ncbi Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance
    J Tilman Gerlach
    Medical Department II, Klinikum Grosshadern and Institute for Immunology, Schwabing, Munich, Germany
    Gastroenterology 125:80-8. 2003
    ..The aim of this study was to define the natural course of the disease and to contribute to the development of treatment strategies for acute hepatitis C virus...
  35. ncbi Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy
    Thomas Berg
    Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Universitatsklinikum Charite, Campus Virchow Klinikum, Humboldt Universitat, Berlin, Germany
    Hepatology 37:600-9. 2003
    ..This algorithm recognizes 53.7% of nonresponders previously identified at week 24 of treatment...
  36. ncbi Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin
    Peter Ferenci
    Medical University of Vienna, Vienna, Austria
    J Hepatol 43:425-33. 2005
    ..Prediction of sustained virological response (SVR) during treatment would allow clinicians to identify patients most likely to benefit from therapy...
  37. ncbi Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B
    Patrick Marcellin
    Service d Hepatologie, INSERM Unité 481 and Centre de Recherches Claude Bernard sur les Hépatites Virales, Hopital Beaujon, Clichy, France
    N Engl J Med 351:1206-17. 2004
    ..As a result, nucleoside and nucleotide analogues are typically continued indefinitely, a strategy associated with the risk of resistance and unknown long-term safety implications...
  38. ncbi Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients
    Manuel Romero-Gomez
    Hepatology Unit, Hospital Universitario de Valme, Sevilla, Spain
    Gastroenterology 128:636-41. 2005
    ..We evaluated the effect of insulin resistance and viral factors on sustained virological response in patients with chronic hepatitis C treated with peginterferon plus ribavirin...
  39. ncbi Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C
    Michael von Wagner
    Universitatsklinikum des Saarlandes, Homburg Saar, Germany
    Gastroenterology 129:522-7. 2005
    ..Whether shorter treatment durations are possible for these patients without compromising sustained virologic response rates is unknown...
  40. ncbi Side effects of therapy for chronic hepatitis C
    Mark W Russo
    Division of Digestive Diseases, University of North Carolina at Chapel Hill, 27599, USA
    Gastroenterology 124:1711-9. 2003
  41. ncbi Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a
    Harald Hofer
    Department of Internal Medicine IV, University of Vienna, Austria
    Am J Gastroenterol 97:2880-5. 2002
    ..Furthermore, the effect of hepatitis C virus (HCV) eradication by antiviral therapy on serum cholesterol levels was studied...
  42. pmc Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin
    Eric Snoeck
    Exprimo NV, Lummen, Belgium, F Hoffmann La Roche Nutley, NJ, USA
    Br J Clin Pharmacol 62:699-709. 2006
    ..To assess the likelihood of a sustained virological response (SVR) vs. the likelihood of anaemia in patients with chronic hepatitis C...
  43. ncbi Hepatitis C treatment of opioid dependants receiving maintenance treatment: results of a Norwegian pilot study
    Aud L Krook
    Unit for Addiction Medicine, Institute of Psychiatry, University of Oslo, and Clinic of Abuse and Dependence, Aker University Hospital HF, Oslo, Norway
    Eur Addict Res 13:216-21. 2007
    ..This study was undertaken to determine whether HCV combination therapy with pegylated interferon alpha-2a plus ribavirin is feasible, efficient and safe in this patient group...
  44. ncbi Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial
    Marina Nunez
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid 28029, Spain
    AIDS Res Hum Retroviruses 23:972-82. 2007
    ..The use of RBV 1000-1200 mg/day plus pegIFN is relatively safe and provides SVR in nearly half of coinfected patients, twice as high in HCV-2/3 than HCV-1/4...
  45. pmc Insulin resistance and hepatitis C
    Manuel Romero-Gomez
    Unit for The Clinical Management of Digestive Diseases Hospital Universitario de Valme Ctra de Cadiz s n Sevilla 41014, Spain
    World J Gastroenterol 12:7075-80. 2006
    ..In summary, hepatitis C promotes insulin resistance and insulin resistance induces interferon resistance, steatosis and fibrosis progression...
  46. ncbi Predictors of response of US veterans to treatment for the hepatitis C virus
    Lisa I Backus
    Center for Quality Management in Public Health, Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA
    Hepatology 46:37-47. 2007
    ..For genotype 3 patients, only receiving PEG-INF 2A affected the likelihood of an SVR; its effect was positive...
  47. pmc Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: impact of bilharziasis and fibrosis stage
    M F Derbala
    Department of Gastroenterology and Hepatology, Hamad Medical Corporation, Doha, Qatar
    World J Gastroenterol 12:5692-8. 2006
    ..To evaluate pegylated interferon alpha2a (PegIFN-alpha2a) in Egyptian patients with HCV genotype 4, and the impact of pretreatment viral load, co-existent bilharziasis and histological liver changes on response rate...
  48. pmc Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy
    Maureen J Donlin
    Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, 1402 S Grand Blvd, Saint Louis, MO 63104, USA
    J Virol 81:8211-24. 2007
    ..No evidence was found for novel HCV strains in the AA population, implying that AA patients may be infected with a higher proportion of the same resistant strains that are found in CA patients...
  49. ncbi Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment
    Jose M Sanchez-Tapias
    Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain
    Gastroenterology 131:451-60. 2006
    ..This study investigated whether treatment for 72 weeks increases the rate of SVR in patients with detectable hepatitis C virus (HCV)-RNA levels at week 4 of treatment...
  50. ncbi Hematologic side effects of interferon and ribavirin therapy
    Kris V Kowdley
    University of Washington, Seattle, WA 98195, USA
    J Clin Gastroenterol 39:S3-8. 2005
    ..The incidence, magnitude, and possible mechanisms of hematologic complications associated with interferon and ribavirin are described in this review...
  51. ncbi Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer
    S Pyrhonen
    Helsinki University Central Hospital, Helsinki, Finland
    J Clin Oncol 17:2859-67. 1999
    ..However, no prospective randomized trial has shown that this treatment prolongs overall survival. We compared overall survival after treatment with IFNalpha2a plus VLB versus VLB alone in patients with advanced renal cell cancer...
  52. ncbi Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial
    G Steineck
    Department of Oncology (Radiumhemmet, Karolinska Hospital, Stockholm, Sweden
    Acta Oncol 29:155-62. 1990
    ..Antibodies to interferon developed frequently in patients receiving high dose oligomeric interferon therapy but rarely in patients receiving low dose monomeric interferon treatment...
  53. ncbi A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C
    K L Lindsay
    University of Southern California, Los Angeles, CA 90033, USA
    Hepatology 34:395-403. 2001
    ..The higher rate of virologic response during treatment with 1.5 microg/kg peginterferon alfa-2b in patients infected with genotype 1 and high viral levels warrants further evaluation...
  54. ncbi Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C
    K R Reddy
    University of Miami School of Medicine, Miami, FL, USA
    Hepatology 33:433-8. 2001
    ..The 180-microg PEG(40kd) IFN alpha-2a dose appeared to be the optimal dose based on sustained virological response and its associated side-effect profile...
  55. ncbi Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy
    Tsung Ming Chen
    Division of Hepato Gastroenterology, Department of Internal Medicine, Tungs Taichung Metroharbor Hospital, Taichung, Taiwan
    J Gastroenterol Hepatol 22:669-75. 2007
    ..The aim of this study was to investigate the predictors of elevated serum AFP in patients with CHC, and its change after Peg-IFN/RBV therapy...
  56. pmc Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C
    M Diago
    Section of Hepatology, University General Hospital, Valencia, Spain
    Gut 55:374-9. 2006
    ..Increased serum and intrahepatic interferon gamma inducible protein 10 (IP-10) levels in patients with chronic hepatitis C (CHC) have been described...
  57. ncbi Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial
    Alessandra Mangia
    Gastroenterology, Istituto di Ricovero e Cura a Carattere Scientifico, Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
    Hepatology 47:43-50. 2008
    ..RVR patients with baseline viremia >or=400,000 IU/mL achieved higher SVR rates when treated for 48 weeks rather than 24 weeks (86.8% versus 73.1%, P = 0.14). The only predictive factor of SVR in RVR patients was advanced fibrosis...
  58. ncbi Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin
    Thomas Berg
    Universitatsklinikum Charite, Campus Virchow Klinikum, Universitatsmedizin Berlin, Germany
    Gastroenterology 130:1086-97. 2006
    ..The extension of treatment duration beyond 48 weeks is one possible strategy to address this problem...
  59. ncbi Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients
    Jose A Mira
    Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario de Valme, Sevilla, Spain
    Antivir Ther 12:1225-35. 2007
    ..The objective of this study was to identify predictors of severe haematological toxicity among HIV-HCV-coinfected patients treated with PEG-IFN plus RBV...
  60. ncbi Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response
    Peter Ferenci
    Department of Internal Medicine III, Medical University, Vienna, Austria
    Gastroenterology 135:451-8. 2008
    ....
  61. ncbi A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3
    Peter Ferenci
    Department of Internal Medicine III, Medical University, Vienna, Austria
    Hepatology 47:1816-23. 2008
    ..4%-83.7%) in group B. Relapse rates in the 2 treatment groups were similar (17% in group A and 20% in group B). The incidence of adverse events, laboratory abnormalities, and dose reductions was similar in the 2 treatment groups...
  62. pmc Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin
    Natalia Laufer
    Infectious Diseases Unit, Hospital Clinic, Barcelona, Spain
    Antivir Ther 13:953-7. 2008
    ..The aim of our study was to evaluate the effect of ABC on the response rate to HCV therapy...
  63. ncbi International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C
    Stefan Zeuzem
    Saarland University Hospital, Homburg Saar, Germany
    J Hepatol 43:250-7. 2005
    ..The aim of this study was to increase virologic response rates by individualized treatment according to the early virologic response...
  64. ncbi Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir
    Eugenia Vispo
    Hospital Carlos III, Madrid, Spain
    Antivir Ther 13:429-37. 2008
    ..There is little information about the influence of antiretroviral drugs on the antiviral activity of pegylated interferon (PEG-IFN) plus ribavirin (RBV) against hepatitis C virus (HCV)...
  65. ncbi Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial
    Ming Lung Yu
    Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
    Hepatology 47:1884-93. 2008
    ..6%), respectively. Multivariate analysis in all patients showed that RVR was the strongest independent factor associated with an SVR, followed by treatment duration, mean weight-based exposure of ribavirin, and baseline viral load...
  66. ncbi Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC
    Nina Aass
    Department of Clinical Cancer Research, The Norwegian Radium Hospital, 0310 Oslo, Norway
    J Clin Oncol 23:4172-8. 2005
    ....
  67. ncbi Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites
    Andrew J Muir
    Division of Gastroenterology, Duke University, Durham, NC, USA
    N Engl J Med 350:2265-71. 2004
    ..The increased prevalence of infection with hepatitis C virus (HCV) genotype 1, which has a lower response rate than other genotypes, has been suggested as the cause...
  68. ncbi Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C
    Gary L Davis
    Division of Hepatology, Baylor University Medical Center, Dallas, TX 75246, USA
    Hepatology 38:645-52. 2003
    ..Patients who fail to achieve EVR will not clear virus even if an additional 9 months of therapy is received. Therapy can be confidently discontinued in those cases...
  69. ncbi Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients
    J Berenguer
    Hospital Gregorio Maranon, Madrid, Spain
    J Antimicrob Chemother 63:1256-63. 2009
    ..We compared the effectiveness and safety of peg-IFN-alpha2a and peg-IFN-alpha2b, both with ribavirin, against chronic hepatitis C virus (HCV) infection in HIV-infected patients...
  70. ncbi Peginterferon and ribavirin for chronic hepatitis C
    Jay H Hoofnagle
    Liver Disease Research Branch, Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA
    N Engl J Med 355:2444-51. 2006
  71. ncbi High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C
    Karin Lindahl
    Department of Infectious Diseases, Karolinska University Hospital Huddinge, Karolinska Institute, Stockholm, Sweden
    Hepatology 41:275-9. 2005
    ..In conclusion, a high dose of ribavirin according to an individualized schedule is feasible but associated with more frequent and serious side effects such as anemia. The viral response merits further evaluation...
  72. ncbi Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies
    Thomas E Hutson
    Baylor University Medical Center, Sammons Cancer Center, Dallas, Texas 75246, USA
    Oncologist 13:1084-96. 2008
    ..Recognition and prompt management of side effects are important to avoid unnecessary dose reductions that may result in suboptimal efficacy...
  73. ncbi Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C
    P Bailon
    Hoffmann La Roche Inc, Nutley, New Jersey 07110, USA
    Bioconjug Chem 12:195-202. 2001
    ..Results of Phase II/III hepatitis C clinical trials in humans confirmed the superior efficacy of pegylated interferon alpha-2a compared to unmodified interferon alpha-2a...
  74. ncbi Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C
    C M Perry
    Adis International Limited, Auckland, New Zealand
    Drugs 61:2263-88. 2001
    ..Headache, fatigue and myalgia are among the most common adverse events...
  75. ncbi Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a
    S Zeuzem
    Medizinische Klinik II, Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt am Main, Germany
    Gastroenterology 120:1438-47. 2001
    ..The aim of the study was to compare viral kinetics in patients treated with standard or peginterferon alpha2a...
  76. ncbi Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin
    Michael W Fried
    University of North Carolina, Chapel Hill, NC 27514, USA
    Hepatology 48:1033-43. 2008
    ..The arm with the higher doses of both drugs was less well-tolerated than the other regimens...
  77. ncbi Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons
    D Alvarez
    Drexel University College of Medicine, Philadelphia, PA, USA
    J Viral Hepat 13:683-9. 2006
    ..However, ZDV use was not associated with higher rates of treatment discontinuation or lower early virologic response rates. HIV and hepatitis C care providers should be cognizant of these data...
  78. ncbi Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia
    Janus P Ong
    Center for Liver Diseases, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042, USA
    Cleve Clin J Med 71:S17-21. 2004
    ..The impact of growth factors on sustained virologic response and their cost-effectiveness in patients with chronic hepatitis C need further assessment...
  79. pmc Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection
    Thomas J Chambers
    Department of Molecular Microbiology and Immunology, St Louis University School of Medicine, St Louis University Health Sciences Center, St Louis, Missouri, USA
    J Virol 79:3071-83. 2005
    ..One interpretation of these data is that early viral responses are governed to some extent by viral factors, whereas sustained responses may be more influenced by host factors, in addition to effects of viral complexity and diversity...
  80. pmc Diagnosis and treatment of chronic hepatitis C infection
    Keyur Patel
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27707, USA
    BMJ 332:1013-7. 2006
  81. pmc Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy
    H Le Guillou-Guillemette
    Laboratory of Virology, Department of Infectious Agents, University Hospital of Angers, 4 rue Larrey, 49933 Angers Cedex 9, France
    World J Gastroenterol 13:2416-26. 2007
    ..Both mechanisms of the Interferon resistance and of the new antiviral drugs are described in this review...
  82. pmc Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome
    Patrizia Farci
    Department of Medical Sciences, University of Cagliari, 09124 Cagliari, Italy
    Proc Natl Acad Sci U S A 99:3081-6. 2002
    ....
  83. ncbi Expression modes of interferon-alpha inducible genes in sensitive and resistant human melanoma cells stimulated with regular and pegylated interferon-alpha
    Ulrich Certa
    Roche Center for Medical Genomics, F Hoffmann La Roche, Ltd, Postfach, Building 93 610, CH 4070 Basel, Switzerland
    Gene 315:79-86. 2003
    ..Finally, we propose that the ISRGs are activated downstream of the primary response genes by a molecule or pathway, which awaits identification, and interferon inducible gene expression is thus more complicated than previously thought...
  84. ncbi Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD)
    Samuel S Lee
    Faculty of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, Canada T2N 4N1
    J Hepatol 37:500-6. 2002
    ..We evaluated the prognostic value of baseline factors and early viral RNA among patients treated with peginterferon alfa-2a (40KD)...
  85. ncbi Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial
    Sylvie Negrier
    Universite de Lyon, Department of Medical Oncology and Cytokines and Cancer Research Unit, Leon Berard Center, INSERM U590, Lyon, France
    Cancer 110:2468-77. 2007
    ..The Programme Etude Rein Cytokines (PERCY) Quattro trial was designed to evaluate both cytokines for their survival benefit to intermediate prognosis patients, who represent the majority of candidates for these treatments...
  86. ncbi Pegylated interferons for chronic hepatitis B
    Antonio Craxi
    Divisione di Gastroenterologia, Instituto di Clinica Medica Policlinico, University di Palermo, Piazzale Delle Cliniche 2, 90127 Palermo, Italy
    Antiviral Res 60:87-9. 2003
    ..In conclusion, peginterferon alpha-2a (40 kDa) is a promising emerging therapy for CHB...
  87. ncbi Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies
    Peter Ferenci
    Department of Internal Medicine IV, Gastroenterology and Hepatology, University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    J Antimicrob Chemother 53:15-8. 2004
    ..Patients who become HCV-RNA negative after 4 weeks have the best chance of achieving an SVR. The rapidity of viral elimination may be a useful guide to tailoring the length of treatment in patients with an EVR...
  88. ncbi Weight-based versus fixed dosing of peginterferon (40kDa) alfa-2a
    Matthew W Lamb
    Department of Clinical Science, Hoffmann LaRoche Inc, 340 Kingsland Street, Nutley, NJ 07110 1199, USA
    Ann Pharmacother 36:933-5. 2002
  89. ncbi Interferon and ribavirin with or without amantadine for interferon non-responders with chronic hepatitis C. A randomized, controlled pilot study
    Christa Wenger
    Gastroenterology and Hepatology, University Hospital Zurich, Switzerland
    Swiss Med Wkly 137:418-23. 2007
    ..Our aim was to compare efficacy and tolerability of an interferon-alfa-2a (INF), ribavirin (RIBA) and amantadine (AMA) combination with those of an INF and RIBA combination...
  90. ncbi Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C
    Sanaa M Kamal
    Department of Internal Medicine II, Gastroenterology and Hepatology, University of Freiburg, Germany
    Gastroenterology 123:1070-83. 2002
    ..This study investigated if the greater efficacy of pegylated IFNs might be related to modulation of immunologic responses...
  91. ncbi Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection
    Abdurrahman Sagir
    Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Universitätsklinik Düsseldorf, Dusseldorf, Germany
    Liver Int 27:954-9. 2007
    ..In this report, we investigated response rates to combination therapy [standard IFN-alpha or PEG-IFN-alpha and ribavirin] in patients who relapsed or failed in prior therapy...
  92. ncbi Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders
    Brian L Pearlman
    Center For Hepatitis C, Atlanta Medical Center, Atlanta, GA 30309, USA
    Hepatology 46:1688-94. 2007
    ..Overall, the rate of SVR was superior in patients treated for 72 weeks versus 48 weeks (38% versus 18%, respectively; P = 0.026)...
  93. ncbi Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C
    Karen L Lindsay
    Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
    Clin Gastroenterol Hepatol 6:234-41. 2008
    ..Although viral kinetic profiles in treatment responders shed light on the mechanism of action of interferon and ribavirin, minimal information is available to explain why some patients experience little or no virologic suppression...
  94. ncbi Future trends in managing hepatitis C
    John G McHutchison
    Division of Gastroenterology and GI Hepatology Research, Duke Clinical Research Institute, Duke University Medical Center, P O Box 17969, Durham, NC 27710, USA
    Gastroenterol Clin North Am 33:S51-61. 2004
    ..Multiple-drug regimens will likely be required to enhance viral clearance and reduce viral resistance, while providing greater tolerability...
  95. ncbi Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1
    Lennox J Jeffers
    Miami Veterans Affairs Medical Center, Miami, FL, USA
    Hepatology 39:1702-8. 2004
    ....
  96. ncbi Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University, Richmond, 23298, USA
    Gastroenterology 126:1015-23; discussion 947. 2004
    ..This study evaluated the effectiveness of this treatment in patients who were nonresponders to previous interferon-based therapy...
  97. ncbi Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C
    Stefan Zeuzem
    JW Goethe University Hospital, Frankfurt, Germany
    Hepatology 48:407-17. 2008
    ..At week 12, mean treatment-associated missed workdays were significantly lower with alb-IFN 900 mug q2wk versus PEG-IFNalpha-2a (1.1 versus 4.3 days; P = 0.006)...
  98. ncbi A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE)
    Marcelo Silva
    Hospital Universitario Austral, Pilar, Argentina
    J Hepatol 45:204-13. 2006
    ..To compare the pharmacokinetics, pharmacodynamics, and antiviral activity of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C virus genotype 1...
  99. ncbi Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin
    V K Rustgi
    Liver Transplantation Unit, Georgetown University Medical Center, Washington, DC, USA
    Aliment Pharmacol Ther 27:433-40. 2008
    ....
  100. ncbi Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy
    Ibrahim A Hanouneh
    Department of Internal Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
    Liver Transpl 14:53-8. 2008
    ..Given its high PPV and NPV, RVR appears to be the most appropriate decision time point for continuation of therapy...
  101. ncbi Very early viral kinetics on interferon treatment in chronic hepatitis C virus genotype 4 infection
    Wolfgang Jessner
    Department of Internal Medicine III, Gastroenterology and Hepatology, Vienna Medical University, Vienna, Austria
    Antivir Ther 13:581-9. 2008
    ..Our aim was to investigate this approach in genotype 4 patients...

Research Grants59

  1. SUBMACULAR SURGERY TRIALS--PHOTOGRAPH READING CENTER
    Susan Bressler; Fiscal Year: 2003
    ..BUDGET NOTE: NEI Staff should evaluate the requested budget in light of their experience with the budget needs of reading centers in other clinical trials. ADMINISTRATIVE NOTE: Awards, if made, are limited to 5 years. ..
  2. Directly Observed Hepatitis C Treatment in Methadone Clinics
    ALAIN LITWIN; Fiscal Year: 2012
    ..Findings from this project will be used to inform the development of a large randomized trial of the efficacy and cost-effectiveness of modified directly observed HCV care versus regular on-site care. ..
  3. HCV TREATMENT IN AFRICAN AMERICANS VS NON HISPANIC WHIT*
    Lennox Jeffers; Fiscal Year: 2005
    ..SPECIFIC AIM 7. To identify sociodemographic (e.g., age, education income, gender, ethnicity) and psychosocial (e.g., anxiety, depression, coping) predictors of adherence to treatment and virologic response to HCV RNA. ..
  4. Non-toxic Human Interferon-Alpha Analog
    Lorelie Villarete; Fiscal Year: 2004
    ..If this project is successful, it should be possible to administer NLVgalpha2b to patients in higher doses than can be achieved with current IFNalpha's, resulting in improved clinical outcomes. ..
  5. HEPATITIS C VIRAL QUASISPECIES WITHIN THE LIVER
    Adrian Di Bisceglie; Fiscal Year: 2003
    ..These studies have great potential significance for understanding of viral clearance, development of persistent infection and for the development of a vaccine against HCV. ..
  6. Molecular Basis Of Renal Cell Carcinoma Response to SU11428
    Robert J Motzer; Fiscal Year: 2011
    ..These tumor and cell line-based studies lay a foundation for further molecular studies aimed at understanding the sensitivity/resistance of RCC to SU11248. ..
  7. CLINICAL TRIALS AND MENTORING IN ONCOLOGY RESEARCH
    Robert Motzer; Fiscal Year: 2003
    ..One recently joined staff at MSKCC in the Genito-urinary Section. Mentoring of clinical trials is extended beyond fellowship to junior faculty members. ..
  8. Antiretroviral Therapy and the Hepatitis C Virus
    Kenneth E Sherman; Fiscal Year: 2010
    ....
  9. HCV Genomic Variability in HIV Infected Hemophiliacs
    Kenneth Sherman; Fiscal Year: 2004
    ..Treatment nonresponders will be followed in a prospective cohort study for up to 3 additional years so that the evolution of the virus, and its associated immune response in this group can be evaluated. ..
  10. Mechanisms of Innate and Adaptive Immunity In HCV
    David Nelson; Fiscal Year: 2009
    ..A better understanding of the immunologic factors that determine resolution or persistence of the infection may help in the design of therapies and vaccines for the control of HCV infection. ..
  11. Eliciting Patient Treatment Preferences for Osteoporosis
    Liana Fraenkel; Fiscal Year: 2008
    ..abstract_text> ..
  12. Chemical Genetics:Cellular Regulators of HCV (RMI)
    Raymond Chung; Fiscal Year: 2004
    ..Second, discovery of hit compounds that positively or negatively regulate HCV replication will ultimately help lead to identification of novel cellular targets that can be exploited to further interrupt the viral lifecycle. ..
  13. Baltimore VIRAHEP-C Clinical Center
    Charles Howell; Fiscal Year: 2005
    ..These studies may provide important new insights into the pathogenesis of HCV and lead to novel therapies for chronic HCV. ..
  14. Pathophysiology and Characterisation of NAFLD
    Michael Charlton; Fiscal Year: 2009
    ..We believe that these experiments will generate mechanistic insight into the cause and effects of increased oxidative stress in patients with histologically progressive NAFLD. ..
  15. RECURRENT HEPATITIS B AFTER LIVER TRANSPLANTATION
    Anna Lok; Fiscal Year: 2007
    ..abstract_text> ..
  16. Differential cytokine responses in Hep C patients.
    Milton Taylor; Fiscal Year: 2005
    ..We will attempt to establish an in vitro system that mimics in vivo events. This combination of experiments should identify factors that are important in the differential responses to treatment and viral resistance. ..
  17. HIV-Hepatitis C Virus Interactions and Pathogenesis
    Raymond T Chung; Fiscal Year: 2010
    ..These studies will shed considerable light on HIV-HCV pathogenic interactions and offer a means of productively disrupting these interactions. ..
  18. CELLULAR IMMUNE RESPONSE IN CHRONIC HEPATITIS C
    David Nelson; Fiscal Year: 2003
    ..These studies will provide insight into basic immunologic principles associated with the host's immune response to this viral infection, as well as provide the basis for new interventional strategies. ..
  19. NOVEL ANIMAL MODELS OF HCV-RELATED HEPATOCARCINOGENESIS
    Raymond Chung; Fiscal Year: 2003
    ..Together, these models will help provide insights into the factors responsible for this devastating complication of chronic HCV infection. ..
  20. VIRAHEP-C Clinical Center
    Anna Lok; Fiscal Year: 2005
    ..abstract_text> ..
  21. T Cell Immunity & Liver Fibrosis in HCV/HIV Coinfection
    Chihiro Morishima; Fiscal Year: 2003
    ..Finally, we will test the hypotheses that HCV/HIV coinfected subjects treated with HAART will demonstrate improved HCV-specific CD4+ T cell function that is not fibrogenic, and is sequestered to the liver. ..
  22. Signaling Pathways in Hepatic Fibrogenesis
    Bruce Bacon; Fiscal Year: 2005
    ..Since activated HSC play a key role in hepatic fibrogenesis, these experiments will contribute to an improved understanding of the basic biochemical processes underlying hepatic fibrosis. ..
  23. U.T. SOUTHWESTERN ADULT AIDS CLINICAL TRIALS UNIT
    Mamta Jain; Fiscal Year: 2008
    ..abstract_text> ..
  24. Resolution of Acute Hepatitis B Virus Infections in Chimpanzees
    Robert Lanford; Fiscal Year: 2008
    ..Our long-term objective is to apply our understanding of the resolution of acute HBV infection to the development of effective new immunotherapies for chronic HBV infections. [unreadable] [unreadable] [unreadable]..
  25. Treatment Disparities/Outcomes of HCV-HIV Co-Infection
    Adeel Butt; Fiscal Year: 2007
    ..The long term objective of the applicant is to make a clinically relevant impact on the HCV treatment patterns and outcomes, especially in the HCV-HIV co-infected patients. [unreadable] [unreadable] [unreadable] [unreadable]..
  26. Quality of Life Therapy for Adults with ESRD Awaiting Renal Transplantation
    James Rodrigue; Fiscal Year: 2007
    ..These benefits have the potential to extend the QOL outcomes otherwise derived from transplantation alone. [unreadable] [unreadable] [unreadable]..
  27. HCV-HIV Coinfection: Impact of Immune Dysfunction
    Richard Sterling; Fiscal Year: 2007
    ..The K-23 award will protect this candidates time and help him mature into a senior investigator in Hepatology. ..
  28. Relationship of metabolic abnormalities to hepatic steatosis in HIV
    Richard Sterling; Fiscal Year: 2008
    ..If our hypothesis is correct, this work could result in a dramatic change in the long-term care of the over 1 million HIV infected individuals in the US. [unreadable] [unreadable]..
  29. Phase I study of 5-aza-2?-deoxycitidine in acute lymphocytic leukemia
    Guillermo Garcia Manero; Fiscal Year: 2008
    ..In this proposal, we plan to develop a new form of low-dose chemotherapy, decitabine, for these patients. Early results indicate that this is active and safe. [unreadable] [unreadable] [unreadable]..
  30. GBV-B: A SMALL PRIMATE MODEL FOR HEPATITIS C INFECTION
    Robert Lanford; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  31. Innate Immune Responses During Therapy for Chronic HCV
    HUGO ROSEN; Fiscal Year: 2009
    ..abstract_text> ..
  32. Pegylated Interferon +/- Ribavirin for Children with HCV
    Kathleen Schwarz; Fiscal Year: 2008
    ..Other endpoints include biochemical and clinical safety assessments. This trial would thus provide critically needed data to guide safe and effective treatment of CHC, a major cause of liver disease in children [unreadable] [unreadable]..
  33. Nonalcoholic steatohepatitis and Cytochrome P450 Enzymes
    Naga P Chalasani; Fiscal Year: 2010
    ..Additionally, we examine the relationship between this enzyme activity and the degree of insulin resistance and lipid peroxidation. ..
  34. Cellular Immunity to Chlamydua at the Epithelial Interface
    RAYMOND MORRIS JOHNSON; Fiscal Year: 2010
    ..Defining what protective T cells look like, and how they function, will be critical for designing and assessing future Chlamydia candidate vaccines. ..
  35. Project ECHO Extension for Community Healthcare Outcomes
    Sanjeev Arora; Fiscal Year: 2006
    ....
  36. Phase1/11 study of 5-aza-2'-deoxycytidine and valproic *
    Guillermo Garcia Manero; Fiscal Year: 2005
    ..Decitabine will be generously provided by SuperGen (r). Valproic acid is an FDA approved anti-convulsant. ..
  37. Cell Cycle Controlling Genes in Adult Acute Lymphoma
    Guillermo Garcia Manero; Fiscal Year: 2005
    ..abstract_text> ..
  38. Repression of Oral Virus by Interferon & Nuclear Bodies
    Jerry Taylor; Fiscal Year: 2004
    ..This understanding should allow the development of strategies for treatment of secondary viral infections in the oral cavity of HIV-infected individuals that enhance or mimic these repressive activities. ..
  39. Immunobiology of Chlamydia
    Raymond Johnson; Fiscal Year: 2004
    ..3) To determine the effect of adoptive transfer of mucosal CD8 and CD4 T lymphocytes on the natural course of MoPn genital tract infections. ..
  40. MENTORED ORIENTED RESEARCH CAREER DEVELOPMENT AWARD
    Jared Gollob; Fiscal Year: 2004
    ....
  41. EVALUATION OF A CONCEPTUAL MODEL OF ORGAN DONATION
    James Rodrigue; Fiscal Year: 2004
    ..abstract_text> ..
  42. VIRAL HEPATITIS IN CHILDREN OF INJECTION DRUG USERS
    Kathleen Schwarz; Fiscal Year: 2003
    ....
  43. Interferon-gamma To Treat Chronic HCV Infection
    Andrew Muir; Fiscal Year: 2002
    ..Secondary endpoints include the biochemical response, inflammatory and regulatory cytokine levels, and quality of life during treatment. ..
  44. Innate Corneal Cell Immunity to Virus Infection
    Jerry Taylor; Fiscal Year: 2004
    ..This knowledge may be utilized to enhance this innate antiviral response and thereby limit initial and recurrent viral infections in the eye. ..
  45. HCV VARIANTS AND IMMUNE RESPONSE IN INJECTION DRUG USERS
    Teresa Wright; Fiscal Year: 2004
    ..Finally, with the establishment of this cohort, we will be able to store serum and lymphocytes for future analysis of genetic determinants of viral persistence/clearance. ..
  46. Proteomics and Biomarkers for Hepatocellular Cancer
    Nezam Afdhal; Fiscal Year: 2004
    ..These studies may lead to identification of more specific and sensitive biomarkers for HCC in HCV which can then be validated further in prospective clinical trials. ..
  47. Cellular Immunity to Hepatitis C Virus in HIV
    Camilla Graham; Fiscal Year: 2005
    ....
  48. Cytokine Inhibition in Hepatocellular Carcinoma
    Jonathan Schwartz; Fiscal Year: 2005
    ....
  49. PROTEIN LIPID INTERACTIONS IN GALLSTONE PATHOGENESIS
    Nezam Afdhal; Fiscal Year: 2002
    ..These studies may lead to strategies for the prevention and non-surgical therapy of this very common disease. ..
  50. Functional Analysis of HCV-B Lymphocyte Interactions
    Thomas Chambers; Fiscal Year: 2003
    ..abstract_text> ..
  51. Race & Viral Resistance in Chronic Hepatitis C (VIRAHEP*
    Robert Brown; Fiscal Year: 2005
    ..abstract_text> ..
  52. Antiviral Therapy in African Americans with HCV
    Nezam Afdhal; Fiscal Year: 2005
    ..Specimens of liver tissue and serum will be collected for basic studies on viral resistance. These studies should help determine the best therapy for AA with HCV. ..
  53. Gene Expression Analyses During IFN Antiviral Therapy
    Robert Lanford; Fiscal Year: 2005
    ..These data will help determine why interferon therapy is often unsuccessful for chronic HCV infections and provide cellular targets for future therapies. ..
  54. CYCLOOXYGENASE-2 AND XENOBIOTICS IN VASCULAR INJURY
    Babette Weksler; Fiscal Year: 2005
    ..abstract_text> ..
  55. Pharmacogenetics of lipid response to estrogen therapy
    Jeanette McCarthy; Fiscal Year: 2009
    ..This may result in future clinically useful diagnostic tests that aid postmenopausal women in their decision whether to use estrogen therapy. ..
  56. Addiction Medicine Physicians and Care for Hepatitis C
    ALAIN LITWIN; Fiscal Year: 2003
    ..Data from this study will have relevance to both drug abuse treatment policy and clinical practice. ..
  57. NUCLEOSIDE ANALOGS AS ANTICANCER COMPOUNDS
    Yung Chi Cheng; Fiscal Year: 2007
    ..It should yield novel information for understanding the biochemical determinants of the action of L-OddC, the biochemistry of the enzymes studied and possible novel use of L-OddC for the treatment of solid tumor. ..